Table 2.

Number of patients exposed to each drug since their first eGFR

Calendar years	AZT	3TC	ABC	DDI	DDC	D4T	TDF	FTC	NVP	EFV	FAPV	SQV	IDV	NFV	LPV	ATV
≤1994	101	0	0	34	18	4	0	0	0	0	0	2	0	0	0	0
1995 to 1996	455	292	0	207	268	184	0	0	1	1	0	93	153	1	0	0
1997 to 1998	621	686	34	349	225	559	0	0	150	49	1	246	378	228	1	0
1999 to 2000	762	1056	292	522	105	798	1	3	402	359	32	218	374	379	74	2
2001 to 2002	2050	2936	1211	1218	116	1273	474	29	896	844	159	327	532	462	694	10
2003 to 2004	2731	4081	1676	1230	89	900	1390	179	1114	1021	439	364	488	409	1347	530
2005 to 2006	2768	4481	2128	1030	36	435	2126	1366	1105	1057	878	358	233	240	1453	1314
Overall	4199	5598	2774	2192	461	1920	2508	1375	1865	1790	1135	845	1141	883	2041	1373

3TC, —; ABC, —; DDI, —; DDC, —; D4T, —; TDF, —; FTC, —; NVP, —; EFV, —; FAPV, —; SQV, —; IDV, indinavir; NFV, —; LPV, —; ATV, eGFR, estimated GFR; AZT, aziothymidine.